Human Placentas and the Changing Face of Reproductive Toxicology Testing

Crossmark: check for updates

Authors

  • Paul Brownbill

DOI:

https://doi.org/10.17140/GOROJ-2-e004

Keywords:

Placenta, Perfusion, Models, Reproductive, Toxicology, Testing, Animal

Abstract

Pharmaceuticals are in use by 40-98% of pregnant mothers in the developed world, varying by country. There is a significant potential for obstetricians to further maintain medical prescriptions for chronic diseases during pregnancy, provided there is confidence within the pharmaceutical industry on the safety of their products. The safety of medicinal products incurs several socioeconomic challenges, and the protection of maternal and fetal health is a foremost and top priority.

References

Burden N, Sewell F, Chapman K. Testing chemical safety: what is needed to ensure the widespread application of non-animal approaches? PLoSBiol. 2015; 13: e1002156. doi: 10.1371/journal.pbio.1002156

Willyard C. The boom in mini stomachs, brains, breasts, kidneys and more. Nature. 2015; 523: 520. doi: 10.1038/523520a

Reardon S. ‘Organs-on-chips’ go mainstream. Nature. 2015; 523: 266. doi: 10.1038/523266a

Esch EW, BahinskiA, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov. 2015; 14: 248-260. doi: 10.1038/nrd4539 Gynecol Obstet Res Open J Page e10

Downloads

Published

2015-09-01

How to Cite

Paul Brownbill. (2015). Human Placentas and the Changing Face of Reproductive Toxicology Testing. Gynecology and Obstetrics Research, 2(3), e9-e10. https://doi.org/10.17140/GOROJ-2-e004